Skip to main content
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience 1/2014

01.11.2014 | Review

Multistage drug effects of ketamine in the treatment of major depression

verfasst von: Martin Walter, Shijia Li, Liliana Ramona Demenescu

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Sonderheft 1/2014

Einloggen, um Zugang zu erhalten

Abstract

A substantial number of patients diagnosed with major depression disorder show poor or no response to standard antidepressive drugs. Recent studies showed that ketamine promotes a rapid and sustained antidepressive effect in treatment-resistant depression. Importantly, after a single dose, such antidepressant action appears very fast, reaching maximum efficacy after 1–2 days before it slowly decays after 3–7 days. This temporal pattern is especially interesting since most effects are investigated following single, subanesthetic doses. This means that effects are observed at time points when the blood levels have long fallen below any active threshold. Mechanisms of action thus may be sought either in secondary or compensatory processes, which develop after acute systemic derangement or in molecular downstream mechanisms of action, which after initiation do not require the presence of active drug levels. We here review acute and delayed effects of subanesthetic ketamine infusion and discuss potential origins of antidepressant drug action. We will provide evidences that both acute effects on abnormal network configuration and delayed effects at the level of homeostatic synaptic plasticity may be necessary for antidepressant action. We further argue that such effects should be followed by a temporally well-defined exploitation of these transient changes by therapeutic processes, aiming at sustained changes of network configuration via psychotherapeutic or other methods.
Literatur
1.
Zurück zum Zitat Bobo WV, Chen H, Trivedi MH et al (2011) Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. J Affect Disord 133:467–476. doi:10.1016/j.jad.2011.04.032 PubMed Bobo WV, Chen H, Trivedi MH et al (2011) Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. J Affect Disord 133:467–476. doi:10.​1016/​j.​jad.​2011.​04.​032 PubMed
2.
Zurück zum Zitat Miller AH (2013) Conceptual confluence : the kynurenine pathway as a common target for ketamine and the convergence of the inflammation and glutamate hypotheses of depression. Neuropsychopharmacology 38(9):1607–1608. doi:10.1038/npp.2013.140 PubMedPubMedCentral Miller AH (2013) Conceptual confluence : the kynurenine pathway as a common target for ketamine and the convergence of the inflammation and glutamate hypotheses of depression. Neuropsychopharmacology 38(9):1607–1608. doi:10.​1038/​npp.​2013.​140 PubMedPubMedCentral
3.
Zurück zum Zitat Zarate CA Jr, Singh JB, Carlson PJ et al (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856–864PubMed Zarate CA Jr, Singh JB, Carlson PJ et al (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856–864PubMed
4.
Zurück zum Zitat Berman RM, Cappiello A, Anand A et al (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351–354PubMed Berman RM, Cappiello A, Anand A et al (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351–354PubMed
5.
Zurück zum Zitat Rasmussen KG (2014) Psychiatric side effects of ketamine in hospitalized medical patients administered subanesthetic doses for pain control. Acta Neuropsychiatr 26:230–233PubMed Rasmussen KG (2014) Psychiatric side effects of ketamine in hospitalized medical patients administered subanesthetic doses for pain control. Acta Neuropsychiatr 26:230–233PubMed
6.
Zurück zum Zitat Murrough JW, Iosifescu DV, Chang LC et al (2013) Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 170:1134–1142PubMedPubMedCentral Murrough JW, Iosifescu DV, Chang LC et al (2013) Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 170:1134–1142PubMedPubMedCentral
7.
Zurück zum Zitat Fond G, Loundou A, Rabu C et al (2014) Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Berl) 231(18):3663–3676. doi:10.1007/s00213-014-3664-5 Fond G, Loundou A, Rabu C et al (2014) Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Berl) 231(18):3663–3676. doi:10.​1007/​s00213-014-3664-5
8.
Zurück zum Zitat McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW (2014) A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med 10:1–12 McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW (2014) A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med 10:1–12
9.
Zurück zum Zitat Caddy C, Giaroli G, White TP, Shergill SS, Tracy DK (2013) Ketamine as the prototype glutamatergic antidepressant: pharmacodynamics actions, and a systematic review and meta-analysis of efficacy. Ther Adv Psychopharmacol. doi:10.1177/2045125313507739 Caddy C, Giaroli G, White TP, Shergill SS, Tracy DK (2013) Ketamine as the prototype glutamatergic antidepressant: pharmacodynamics actions, and a systematic review and meta-analysis of efficacy. Ther Adv Psychopharmacol. doi:10.​1177/​2045125313507739​
10.
Zurück zum Zitat Glue P, Gulati A, Le Nedelec M, Duffull S (2011) Dose-and exposure-response to ketamine in depression. Biol Psychiatry 70:e9–e10PubMed Glue P, Gulati A, Le Nedelec M, Duffull S (2011) Dose-and exposure-response to ketamine in depression. Biol Psychiatry 70:e9–e10PubMed
12.
Zurück zum Zitat aan het Rot M, Collins KA, Murrough JW et al (2010) Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 67:139–145PubMed aan het Rot M, Collins KA, Murrough JW et al (2010) Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 67:139–145PubMed
16.
Zurück zum Zitat Rowland LM, Bustillo JR, Mullins PG et al (2005) Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry 162:394–396PubMed Rowland LM, Bustillo JR, Mullins PG et al (2005) Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry 162:394–396PubMed
17.
Zurück zum Zitat Walter M, Henning A, Grimm S et al (2009) The relationship between aberrant neuronal activation in the pregenual anterior cingulate, altered glutamatergic metabolism, and anhedonia in major depression. Arch Gen Psychiatry 66:478–486. doi:10.1001/archgenpsychiatry.2009.39 PubMed Walter M, Henning A, Grimm S et al (2009) The relationship between aberrant neuronal activation in the pregenual anterior cingulate, altered glutamatergic metabolism, and anhedonia in major depression. Arch Gen Psychiatry 66:478–486. doi:10.​1001/​archgenpsychiatr​y.​2009.​39 PubMed
18.
Zurück zum Zitat Salvadore G, Cornwell BR, Sambataro F et al (2010) Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology 35:1415–1422. doi:10.1038/npp.2010.24 PubMedPubMedCentral Salvadore G, Cornwell BR, Sambataro F et al (2010) Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology 35:1415–1422. doi:10.​1038/​npp.​2010.​24 PubMedPubMedCentral
19.
Zurück zum Zitat Brennan BP, Hudson JI, Jensen JE et al (2009) Rapid Enhancement of Glutamatergic Neurotransmission in Bipolar Depression Following Treatment with Riluzole. Neuropsychopharmacology. doi:10.1038/npp.2009.191 Brennan BP, Hudson JI, Jensen JE et al (2009) Rapid Enhancement of Glutamatergic Neurotransmission in Bipolar Depression Following Treatment with Riluzole. Neuropsychopharmacology. doi:10.​1038/​npp.​2009.​191
20.
Zurück zum Zitat Salvadore G, van der Veen JW, Zhang Y et al (2012) An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. Int J Neuropsychop 15:1063–1072. doi:10.1017/S1461145711001593 Salvadore G, van der Veen JW, Zhang Y et al (2012) An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. Int J Neuropsychop 15:1063–1072. doi:10.​1017/​S146114571100159​3
21.
Zurück zum Zitat Mayberg HS, Brannan SK, Mahurin RK et al (1997) Cingulate function in depression: a potential predictor of treatment response. Neuroreport 8:1057–1061PubMed Mayberg HS, Brannan SK, Mahurin RK et al (1997) Cingulate function in depression: a potential predictor of treatment response. Neuroreport 8:1057–1061PubMed
22.
Zurück zum Zitat Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, Jerabek PA (2000) Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry 48:830–843. doi:10.1016/S0006-3223(00)01036-2 PubMed Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, Jerabek PA (2000) Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry 48:830–843. doi:10.​1016/​S0006-3223(00)01036-2 PubMed
23.
Zurück zum Zitat Wehrl HF, Hossain M, Lankes K et al (2013) Simultaneous PET-MRI reveals brain function in activated and resting state on metabolic, hemodynamic and multiple temporal scales. Nat Med. doi:10.1038/nm.3290 PubMed Wehrl HF, Hossain M, Lankes K et al (2013) Simultaneous PET-MRI reveals brain function in activated and resting state on metabolic, hemodynamic and multiple temporal scales. Nat Med. doi:10.​1038/​nm.​3290 PubMed
24.
Zurück zum Zitat Li M, Metzger CD, Li W et al (2014) Dissociation of glutamate and cortical thickness is restricted to regions subserving trait but not state markers in major depressive disorder. JAD. doi:10.1016/j.jad.2014.08.001 Li M, Metzger CD, Li W et al (2014) Dissociation of glutamate and cortical thickness is restricted to regions subserving trait but not state markers in major depressive disorder. JAD. doi:10.​1016/​j.​jad.​2014.​08.​001
25.
Zurück zum Zitat Horn DI, Yu C, Steiner J et al (2010) Glutamatergic and resting-state functional connectivity correlates of severity in major depression: the role of pregenual anterior cingulate cortex and anterior insula. Front Syst Neurosci 4(July):1–10. doi:10.3389/fnsys.2010.00033 Horn DI, Yu C, Steiner J et al (2010) Glutamatergic and resting-state functional connectivity correlates of severity in major depression: the role of pregenual anterior cingulate cortex and anterior insula. Front Syst Neurosci 4(July):1–10. doi:10.​3389/​fnsys.​2010.​00033
34.
Zurück zum Zitat Caldeira MV, Melo CV, Pereira DB, Carvalho RF, Carvalho AL, Duarte CB (2007) BDNF regulates the expression and traffic of NMDA receptors in cultured hippocampal neurons. Mol Cell Neurosci 35:208–219. doi:10.1016/j.mcn.2007.02.019 PubMed Caldeira MV, Melo CV, Pereira DB, Carvalho RF, Carvalho AL, Duarte CB (2007) BDNF regulates the expression and traffic of NMDA receptors in cultured hippocampal neurons. Mol Cell Neurosci 35:208–219. doi:10.​1016/​j.​mcn.​2007.​02.​019 PubMed
36.
Zurück zum Zitat Castren E, Rantamaki T (2010) The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity. Dev Neurobiol 70:289–297. doi:10.1002/dneu.20758 PubMed Castren E, Rantamaki T (2010) The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity. Dev Neurobiol 70:289–297. doi:10.​1002/​dneu.​20758 PubMed
39.
Zurück zum Zitat Brunoni AR, Lopes M, Fregni F (2008) A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 11:1169–1180. doi:10.1017/S1461145708009309 PubMed Brunoni AR, Lopes M, Fregni F (2008) A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 11:1169–1180. doi:10.​1017/​S146114570800930​9 PubMed
41.
Zurück zum Zitat Moghaddam B, Adams B, Verma A, Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17(8):2921–2927PubMed Moghaddam B, Adams B, Verma A, Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17(8):2921–2927PubMed
42.
Zurück zum Zitat Koike H, Iijima M, Chaki S (2011) Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 224:107–111. doi:10.1016/j.bbr.2011.05.035 PubMed Koike H, Iijima M, Chaki S (2011) Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 224:107–111. doi:10.​1016/​j.​bbr.​2011.​05.​035 PubMed
44.
Zurück zum Zitat Zhou W, Wang N, Yang C, Li XM, Zhou ZQ, Yang JJ (2013) Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex. Eur Psychiatry. doi:10.1016/j.eurpsy.2013.10.005 PubMed Zhou W, Wang N, Yang C, Li XM, Zhou ZQ, Yang JJ (2013) Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex. Eur Psychiatry. doi:10.​1016/​j.​eurpsy.​2013.​10.​005 PubMed
46.
Zurück zum Zitat Abel T, Lattal KM (2001) Molecular mechanisms of memory acquisition, consolidation and retrieval. Curr Opin Neurobiol 11:180–187 Abel T, Lattal KM (2001) Molecular mechanisms of memory acquisition, consolidation and retrieval. Curr Opin Neurobiol 11:180–187
50.
Zurück zum Zitat Sharma AC, Kulkarni SK (1991) Effects of MK-801 and ketamine on short-term memory deficits in passive avoidance step-down task paradigm in mice. Methods Find Exp Clin Pharmacol 13:155–159PubMed Sharma AC, Kulkarni SK (1991) Effects of MK-801 and ketamine on short-term memory deficits in passive avoidance step-down task paradigm in mice. Methods Find Exp Clin Pharmacol 13:155–159PubMed
51.
Zurück zum Zitat Pellicano MP, Siciliano F, Sadile AG (1993) NMDA receptors modulate long-term habituation to spatial novelty: dose- and genotype-dependent differential effects of posttrial MK-801 and CPP in rats. Physiol Behav 54:563–568. doi:10.1016/0031-9384(93)90250-J PubMed Pellicano MP, Siciliano F, Sadile AG (1993) NMDA receptors modulate long-term habituation to spatial novelty: dose- and genotype-dependent differential effects of posttrial MK-801 and CPP in rats. Physiol Behav 54:563–568. doi:10.​1016/​0031-9384(93)90250-J PubMed
52.
Zurück zum Zitat Danysz W, Zajaczkowski W, Parsons CG (1995) Modulation of learning processes by ionotropic glutamate receptor ligands. Behav Pharmacol 6:455–474PubMed Danysz W, Zajaczkowski W, Parsons CG (1995) Modulation of learning processes by ionotropic glutamate receptor ligands. Behav Pharmacol 6:455–474PubMed
55.
Zurück zum Zitat Fox CJ, Russell K, Titterness AK, Wang YT, Christie BR (2007) Tyrosine phosphorylation of the GluR2 subunit is required for long-term depression of synaptic efficacy in young animals in vivo. Hippocampus 17:600–605. doi:10.1002/hipo.20302 PubMed Fox CJ, Russell K, Titterness AK, Wang YT, Christie BR (2007) Tyrosine phosphorylation of the GluR2 subunit is required for long-term depression of synaptic efficacy in young animals in vivo. Hippocampus 17:600–605. doi:10.​1002/​hipo.​20302 PubMed
58.
61.
Zurück zum Zitat Holtmaat A, Svoboda K (2009) Experience-dependent structural synaptic plasticity in the mammalian brain. Nat Rev Neurosci 10:647–658. doi:10.1038/nrn2699 PubMed Holtmaat A, Svoboda K (2009) Experience-dependent structural synaptic plasticity in the mammalian brain. Nat Rev Neurosci 10:647–658. doi:10.​1038/​nrn2699 PubMed
64.
Zurück zum Zitat Tabuchi A, Nakaoka R, Amano K et al (2000) Differential activation of brain-derived neurotrophic factor gene promoters I and III by Ca2+ signals evoked via L-type voltage-dependent and N-methyl-D-aspartate receptor Ca2+ channels. J Biol Chem 275:17269–17275. doi:10.1074/jbc.M9095381 PubMed Tabuchi A, Nakaoka R, Amano K et al (2000) Differential activation of brain-derived neurotrophic factor gene promoters I and III by Ca2+ signals evoked via L-type voltage-dependent and N-methyl-D-aspartate receptor Ca2+ channels. J Biol Chem 275:17269–17275. doi:10.​1074/​jbc.​M9095381 PubMed
65.
66.
Zurück zum Zitat Takei N, Inamura N, Kawamura M et al (2004) Brain-derived neurotrophic factor induces mammalian target of rapamycin-dependent local activation of translation machinery and protein synthesis in neuronal dendrites. J Neurosci 24:9760–9769. doi:10.1523/JNEUROSCI.1427-04.2004 PubMed Takei N, Inamura N, Kawamura M et al (2004) Brain-derived neurotrophic factor induces mammalian target of rapamycin-dependent local activation of translation machinery and protein synthesis in neuronal dendrites. J Neurosci 24:9760–9769. doi:10.​1523/​JNEUROSCI.​1427-04.​2004 PubMed
70.
Zurück zum Zitat Tyler WJ, Alonso M, Bramham CR, Pozzo-Miller LD (2002) From acquisition to consolidation: on the role of brain-derived neurotrophic factor signaling in hippocampal-dependent learning. Learn Mem 9:224–237. doi:10.1101/lm.51202 PubMedPubMedCentral Tyler WJ, Alonso M, Bramham CR, Pozzo-Miller LD (2002) From acquisition to consolidation: on the role of brain-derived neurotrophic factor signaling in hippocampal-dependent learning. Learn Mem 9:224–237. doi:10.​1101/​lm.​51202 PubMedPubMedCentral
71.
Zurück zum Zitat Cao W, Duan J, Wang X et al (2014) Early enriched environment induces an increased conversion of proBDNF to BDNF in the adult rat’s hippocampus. Behav Brain Res 265C:76–83. doi:10.1016/j.bbr.2014.02.022 Cao W, Duan J, Wang X et al (2014) Early enriched environment induces an increased conversion of proBDNF to BDNF in the adult rat’s hippocampus. Behav Brain Res 265C:76–83. doi:10.​1016/​j.​bbr.​2014.​02.​022
72.
75.
Zurück zum Zitat Egan MF, Kojima M, Callicott JH et al (2003) The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112:257–269. doi:10.1016/S0092-8674(03)00035-7 PubMed Egan MF, Kojima M, Callicott JH et al (2003) The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112:257–269. doi:10.​1016/​S0092-8674(03)00035-7 PubMed
78.
Zurück zum Zitat Hariri AR, Goldberg TE, Mattay VS et al (2003) Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 23:6690–6694PubMed Hariri AR, Goldberg TE, Mattay VS et al (2003) Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 23:6690–6694PubMed
79.
Zurück zum Zitat Strauss J, Barr CL, George CJ et al (2004) BDNF and COMT polymorphisms: relation to memory phenotypes in young adults with childhood-onset mood disorder. Neuromolecular Med 5:181–192PubMed Strauss J, Barr CL, George CJ et al (2004) BDNF and COMT polymorphisms: relation to memory phenotypes in young adults with childhood-onset mood disorder. Neuromolecular Med 5:181–192PubMed
81.
Zurück zum Zitat Burgdorf J, Zhang X-l, Nicholson KL et al (2012) GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology 38(5):729–742. doi:10.1038/npp.2013.42 PubMed Burgdorf J, Zhang X-l, Nicholson KL et al (2012) GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology 38(5):729–742. doi:10.​1038/​npp.​2013.​42 PubMed
82.
Zurück zum Zitat Gideons ES, Kavalali ET, Monteggia LM (2014) Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses. Proc Natl Acad Sci 111:8649–8654. doi:10.1073/pnas.1323920111 PubMed Gideons ES, Kavalali ET, Monteggia LM (2014) Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses. Proc Natl Acad Sci 111:8649–8654. doi:10.​1073/​pnas.​1323920111 PubMed
85.
Zurück zum Zitat Hetem LA, Danion JM, Diemunsch P, Brandt C (2000) Effect of a subanesthetic dose of ketamine on memory and conscious awareness in healthy volunteers. Psychopharmacology 152(3):283–288. doi:10.1007/s002130000511 PubMed Hetem LA, Danion JM, Diemunsch P, Brandt C (2000) Effect of a subanesthetic dose of ketamine on memory and conscious awareness in healthy volunteers. Psychopharmacology 152(3):283–288. doi:10.​1007/​s002130000511 PubMed
86.
Zurück zum Zitat Honey GD, Honey RA, O’Loughlin C et al (2005) Ketamine disrupts frontal and hippocampal contribution to encoding and retrieval of episodic memory: an fMRI study. Cereb Cortex 15(6):749–759. doi:10.1093/cercor/bhh176 PubMed Honey GD, Honey RA, O’Loughlin C et al (2005) Ketamine disrupts frontal and hippocampal contribution to encoding and retrieval of episodic memory: an fMRI study. Cereb Cortex 15(6):749–759. doi:10.​1093/​cercor/​bhh176 PubMed
88.
Zurück zum Zitat Newcomer JW, Farber NB, Jevtovic-Todorovic V et al (1999) Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20(2):106–118. doi:10.1016/S0893-133X(98)00067-0 PubMed Newcomer JW, Farber NB, Jevtovic-Todorovic V et al (1999) Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20(2):106–118. doi:10.​1016/​S0893-133X(98)00067-0 PubMed
89.
Zurück zum Zitat Venable N, Kelly PH (1990) Effects of NMDA receptor antagonists on passive avoidance learning and retrieval in rats and mice. Psychopharmacology 100(2):215–221. doi:10.1007/BF02244409 PubMed Venable N, Kelly PH (1990) Effects of NMDA receptor antagonists on passive avoidance learning and retrieval in rats and mice. Psychopharmacology 100(2):215–221. doi:10.​1007/​BF02244409 PubMed
90.
Zurück zum Zitat Honey GD, Honey RA, Sharar SR et al (2005) Impairment of specific episodic memory processes by sub-psychotic doses of ketamine: the effects of levels of processing at encoding and of the subsequent retrieval task. Psychopharmacology 181(3):445–457PubMed Honey GD, Honey RA, Sharar SR et al (2005) Impairment of specific episodic memory processes by sub-psychotic doses of ketamine: the effects of levels of processing at encoding and of the subsequent retrieval task. Psychopharmacology 181(3):445–457PubMed
93.
Zurück zum Zitat Greene R (2001) Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia. Hippocampus 11(5):569–577. doi:10.1002/hipo.1072 PubMed Greene R (2001) Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia. Hippocampus 11(5):569–577. doi:10.​1002/​hipo.​1072 PubMed
97.
Zurück zum Zitat Beck AT (1967) Depression: clinical, experimental, and theoretical aspects., xivHoeber Medical Division, New York, p 370 Beck AT (1967) Depression: clinical, experimental, and theoretical aspects., xivHoeber Medical Division, New York, p 370
98.
Zurück zum Zitat Disner SG, Beevers CG, Haigh EA, Beck AT (2011) Neural mechanisms of the cognitive model of depression. Nat Rev Neurosci 12(8):467–477. doi:10.1038/nrn3027 PubMed Disner SG, Beevers CG, Haigh EA, Beck AT (2011) Neural mechanisms of the cognitive model of depression. Nat Rev Neurosci 12(8):467–477. doi:10.​1038/​nrn3027 PubMed
99.
Zurück zum Zitat Murphy FC, Michael A, Robbins TW, Sahakian BJ (2003) Neuropsychological impairment in patients with major depressive disorder: the effects of feedback on task performance. Psychol Med 33(3):455–467. doi:10.1017/S0033291702007018 PubMed Murphy FC, Michael A, Robbins TW, Sahakian BJ (2003) Neuropsychological impairment in patients with major depressive disorder: the effects of feedback on task performance. Psychol Med 33(3):455–467. doi:10.​1017/​S003329170200701​8 PubMed
105.
Zurück zum Zitat Robinson OJ, Cools R, Carlisi CO, Sahakian BJ, Drevets WC (2012) Ventral striatum response during reward and punishment reversal learning in unmedicated major depressive disorder. Am J Psychiatry 169(2):152–159. doi:10.1176/appi.ajp.2011.11010137 PubMed Robinson OJ, Cools R, Carlisi CO, Sahakian BJ, Drevets WC (2012) Ventral striatum response during reward and punishment reversal learning in unmedicated major depressive disorder. Am J Psychiatry 169(2):152–159. doi:10.​1176/​appi.​ajp.​2011.​11010137 PubMed
107.
Zurück zum Zitat Marazziti D, Consoli G, Picchetti M, Carlini M, Faravelli L (2010) Cognitive impairment in major depression. Eur J Pharmacol 626(1):83–86PubMed Marazziti D, Consoli G, Picchetti M, Carlini M, Faravelli L (2010) Cognitive impairment in major depression. Eur J Pharmacol 626(1):83–86PubMed
109.
Zurück zum Zitat Hautzinger M (2008) Psychotherapie der Depression. Bundesgesundheitsbl—Gesundheitsforsch—Gesundheitsschutz Hautzinger M (2008) Psychotherapie der Depression. Bundesgesundheitsbl—Gesundheitsforsch—Gesundheitsschutz
110.
Zurück zum Zitat Swan JS, Macvicar R, Christmas D et al (2014) Cognitive behavioural analysis system of psychotherapy (CBASP) for chronic depression: clinical characteristics and six month clinical outcomes in an open case series. J Affect Disord 152–154:268–276. doi:10.1016/j.jad.2013.09.024 PubMed Swan JS, Macvicar R, Christmas D et al (2014) Cognitive behavioural analysis system of psychotherapy (CBASP) for chronic depression: clinical characteristics and six month clinical outcomes in an open case series. J Affect Disord 152–154:268–276. doi:10.​1016/​j.​jad.​2013.​09.​024 PubMed
113.
Zurück zum Zitat Hofmann SG, Wu JQ, Boettcher, H. (2013) D-cycloserine as an augmentation strategy for cognitive behavioral therapy of anxiety disorders. Biol Mood Anxiety Disord 3(11). doi:10.1186/2045-5380-3-11 Hofmann SG, Wu JQ, Boettcher, H. (2013) D-cycloserine as an augmentation strategy for cognitive behavioral therapy of anxiety disorders. Biol Mood Anxiety Disord 3(11). doi:10.​1186/​2045-5380-3-11
115.
Zurück zum Zitat Vollenweider FX, Kometer M (2010) The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 11(9):642–651. doi:10.1038/nrn2884 PubMed Vollenweider FX, Kometer M (2010) The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 11(9):642–651. doi:10.​1038/​nrn2884 PubMed
118.
Zurück zum Zitat Palomero-Gallagher N, Vogt BA, Schleicher A, Mayberg HS, Zilles K (2009) Receptor architecture of human cingulate cortex: evaluation of the four-region neurobiological model. Hum Brain Map 30:2336–2355. doi:10.1002/hbm.20667 Palomero-Gallagher N, Vogt BA, Schleicher A, Mayberg HS, Zilles K (2009) Receptor architecture of human cingulate cortex: evaluation of the four-region neurobiological model. Hum Brain Map 30:2336–2355. doi:10.​1002/​hbm.​20667
119.
120.
Zurück zum Zitat Niesters M, Khalili-Mahani N, Martini C et al (2012) Effect of subanesthetic ketamine on intrinsic functional brain connectivity: a placebo-controlled functional magnetic resonance imaging study in healthy male volunteers. Anesthesiology 117(4):868–877. doi:10.1097/ALN.0b013e31826a0db3 PubMed Niesters M, Khalili-Mahani N, Martini C et al (2012) Effect of subanesthetic ketamine on intrinsic functional brain connectivity: a placebo-controlled functional magnetic resonance imaging study in healthy male volunteers. Anesthesiology 117(4):868–877. doi:10.​1097/​ALN.​0b013e31826a0db3​ PubMed
121.
Zurück zum Zitat Gass N, Schwarz AJ, Sartorius A et al (2013) Sub-anesthetic ketamine modulates intrinsic BOLD connectivity within the hippocampal-prefrontal circuit in the rat. Neuropsychopharmacology 39:895–906. doi:10.1038/npp.2013.290 PubMed Gass N, Schwarz AJ, Sartorius A et al (2013) Sub-anesthetic ketamine modulates intrinsic BOLD connectivity within the hippocampal-prefrontal circuit in the rat. Neuropsychopharmacology 39:895–906. doi:10.​1038/​npp.​2013.​290 PubMed
122.
Zurück zum Zitat Dou W, Palomero-Gallagher N, van Tol MJ et al (2013) Systematic regional variations of GABA, glutamine, and glutamate concentrations follow receptor fingerprints of human cingulate cortex. J Neurosci 33:12698–12704. doi:10.1523/JNEUROSCI.1758-13.2013 PubMed Dou W, Palomero-Gallagher N, van Tol MJ et al (2013) Systematic regional variations of GABA, glutamine, and glutamate concentrations follow receptor fingerprints of human cingulate cortex. J Neurosci 33:12698–12704. doi:10.​1523/​JNEUROSCI.​1758-13.​2013 PubMed
123.
Zurück zum Zitat Kranaster L, Hoyer C, Janke C, Sartorius A (2014) Preliminary evaluation of clinical outcome and safety of ketamine as an anesthetic for electroconvulsive therapy in schizophrenia. World J Biol Psychiatry 15:242–250. doi:10.3109/15622975.2011.647833 PubMed Kranaster L, Hoyer C, Janke C, Sartorius A (2014) Preliminary evaluation of clinical outcome and safety of ketamine as an anesthetic for electroconvulsive therapy in schizophrenia. World J Biol Psychiatry 15:242–250. doi:10.​3109/​15622975.​2011.​647833 PubMed
127.
Zurück zum Zitat Grimm S, Boesiger P, Beck J et al (2009) Altered negative BOLD responses in the default-mode network during emotion processing in depressed subjects. Neuropsychopharmacology 34(4):932–943. doi:10.1038/npp.2008.81 PubMed Grimm S, Boesiger P, Beck J et al (2009) Altered negative BOLD responses in the default-mode network during emotion processing in depressed subjects. Neuropsychopharmacology 34(4):932–943. doi:10.​1038/​npp.​2008.​81 PubMed
130.
Zurück zum Zitat Hashimoto K, Malchow B, Falkai P, Schmitt A (2013) Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci 263:367–377PubMed Hashimoto K, Malchow B, Falkai P, Schmitt A (2013) Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci 263:367–377PubMed
131.
Metadaten
Titel
Multistage drug effects of ketamine in the treatment of major depression
verfasst von
Martin Walter
Shijia Li
Liliana Ramona Demenescu
Publikationsdatum
01.11.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
European Archives of Psychiatry and Clinical Neuroscience / Ausgabe Sonderheft 1/2014
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI
https://doi.org/10.1007/s00406-014-0535-3

Weitere Artikel der Sonderheft 1/2014

European Archives of Psychiatry and Clinical Neuroscience 1/2014 Zur Ausgabe

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Spezielles Sportprogramm bei einer Reihe von psychischen Erkrankungen effektiv

08.05.2024 Psychotherapie Nachrichten

Sportliche Betätigung hilft nicht nur bei Depression, sondern auch in Gruppen von Patientinnen und Patienten mit unterschiedlichen psychischen Erkrankungen, wie Insomnie, Panikattacken, Agoraphobie und posttraumatischem Belastungssyndrom. Sie alle profitieren längerfristig.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.